Sana Biotechnology
Sana Biotechnology raises $700M IPO at $4.2B valuation
Sana Biotechnology: IPO Funding Round
Sana Biotechnology has successfully raised $700M in IPO funding, reaching a valuation of $4.2B.
Company Overview
Cell and gene therapy platform
Funding Details
The IPO round was led by Flagship Pioneering, with participation from ARCH Venture Partners, F-Prime Capital, Baillie Gifford.
Company Information
- Headquarters: 188 East Blaine Street, Seattle, WA 98102
- Founded: 2018
- Employees: 400+
- Category: Biotech
Investment
Sana Biotechnology plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Flagship Pioneering: Verified investor in IPO
- ARCH Venture Partners: Verified investor in IPO
- F-Prime Capital: Verified investor in IPO
- Baillie Gifford: Verified investor in IPO
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started